Samantha Hitchcock

Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.

The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.

The unique biological characteristics of uveal melanoma have prompted the National Comprehensive Cancer Network to develop the first set of guidelines for the diagnosis and management of the rare cancer.